EX-99.1 2 catx-ex99_1.htm EX-99.1

Slide 1

Corporate Presentation

Slide 2

 

Slide 3

Developing the Next Generation of Targeted Therapies

Slide 4

 

Slide 5

Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

Slide 6

 

Slide 7

Perspective’s Innovative Platform

Slide 8

Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window

Slide 9

 

Slide 10

Proposed Mechanism of Action for 212Pb

Slide 11

Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs

Slide 12

 

Slide 13

 

Slide 14

Perspective’s Pre-Targeting Platform

Slide 15

Supply Chain and Manufacturing Infrastructure

Slide 16

On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products

Slide 17

 

Slide 18

Neuroendocrine Tumors: VMT-⍺-NET

Slide 19

 

Slide 20

 

Slide 21

 

Slide 22

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

Slide 23

Anti-Tumor Activity

Slide 24

Signal of Sustained Anti-Tumor Activity

Slide 25

[212Pb]VMT-α-NET Was Well Tolerated

Slide 26

No Decline in Renal Function Observed

Slide 27

 

Slide 28

Patient with PR after [212Pb]VMT-α-NET

Slide 29

Melanoma Program: VMT01/02

Slide 30

 

Slide 31

 

Slide 32

 

Slide 33

 

Slide 34

Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma

Slide 35

 

Slide 36

Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)

Slide 37

 

Slide 38

 

Slide 39

 

Slide 40

 

Slide 41

 

Slide 42

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma

Slide 43

 

Slide 44

 

Slide 45

 

Slide 46

General Corporate Information

Slide 47

 

Slide 48

 

Slide 49

 

Slide 50

 

Slide 51

Abbreviations